Table 2.
Clinical outcome effect size interpretation, Numbers Needed to Treat, and clinical meaningfulness.
| Clinical measure | Drug(s) included in meta-analysis or subgroup analysis that reached statistical significance | Effect size (Standardized mean difference) | Size of the effect | Number Needed to Treat (NNT) | Point-change approximation on original scale | Minimal score change considered clinically important31 |
|---|---|---|---|---|---|---|
| CDR-SB | Bapineuzumab, Solanezumab, Gantenerumab, Aducanumab, Crenezumab, Lecanemab, Donanemab | −0.06 | Very small | 30 | < 0.70 | 1 |
| Lecanemab | −0.19 | Small | 9 | < 0.70 | 1 | |
| Donanemab | −0.26 | Small to moderate | 7 | 0.70 | 1 | |
| ADAS-Cog | Bapineuzumab, Solanezumab, Gantenerumab, Aducanumab, Crenezumab, Lecanemab, Donanemab | −0.08 | Very small | 22 | < 1.44 | 2 |
| Solanezumab | −0.07 | Very small | 25 | < 1.44 | 2 | |
| Gantenerumab | −0.10 | Very small | 18 | < 1.44 | 2 | |
| Aducanumab | −0.11 | Very small | 16 | < 1.44 | 2 | |
| Lecanemab | −0.16 | Small | 11 | 1.44 | 2 | |
| Donanemab | −0.15 | Small | 12 | < 1.44 | 2 | |
| ADCS-ADL | Solanezumab, Gantenerumab, Aducanumab, Crenezumab, Lecanemab, Donanemab | 0.09 | Very small | 20 | < 2 | - |
| Aducanumab | 0.13 | Very small | 14 | < 2 | - | |
| Lecanemab | 0.25 | Small to moderate | 7 | 2 | - | |
| Donanemab | 0.18 | Small | 10 | < 2 | - | |
| MMSE | Bapineuzumab, Solanezumab, Gantenerumab, Aducanumab, Crenezumab, Donanemab | 0.05 | Very small | 35 | < 0.8 | 2 |
| Solanezumab | 0.08 | Very small | 22 | 0.8 | 2 |